
Applied Clinical Trials

Applied Clinical Trials
Linda Reuter, CIP, Director of BRANY IRB, discusses the Revised Common Rule that now requires informed consent to begin with a concise and focused presentation of key information that will help the patient better understand the reasons why they might or might not want to participate in the research.

Applied Clinical Trials
Irina Petrova, Director of Clinical Operations for OCT Clinical Trials, explores why U.S. companies are turning to Russa after having secured approval for 108 trials there in 2018.

Applied Clinical Trials
Yaky Yanay, CEO of Pluristem, talks with Moe Alsumidaie about his experience and the strategies Pluristem implemented in regenerative medicine clinical trials.

Applied Clinical Trials

Applied Clinical Trials

Applied Clinical Trials

Applied Clinical Trials

Applied Clinical Trials

Applied Clinical Trials

Applied Clinical Trials

Applied Clinical Trials

Applied Clinical Trials

Applied Clinical Trials

Applied Clinical Trials

Applied Clinical Trials

Applied Clinical Trials

Applied Clinical Trials
New rules in Denmark to eliminate potential conflict-of-interest issues follow the lead of the European Medicines Agency's repeated attempts to rebut allegations of pro-industry bias.

Applied Clinical Trials

Applied Clinical Trials

Applied Clinical Trials
MyStudies, introduced by the FDA, bridges data streams to real world evidence by facilitating the collection of real-world data directly from patients in conjunction with a variety of data sources.


Applied Clinical Trials
Peter O'Donnell discusses the European Commission's compendium and how triallists are not only obliged to comply with the current rules, but at the same time to prepare themselves for the future rules.

Applied Clinical Trials
Click the title above to open the Applied Clinical Trials July/August 2019 issue in an interactive PDF format.

Applied Clinical Trials
Yaky Yanay, CEO of Pluristem, will discuss his experience and the strategies Pluristem implemented in regenerative medicine clinical trials.

Applied Clinical Trials
Methods sponsors and CROs can use to minimize the growing pains associated with RBM implementation.

Applied Clinical Trials
Patient advocates debate whether FDA approval on small, early clinical studies is too fast-tracked for efficacy and safety, or too slow due to long review processes.

Applied Clinical Trials
Addressing the current hurdles and potential solutions in nonalcoholic steatohepatitis awareness and clinical trial enrollment.

Applied Clinical Trials
A look at the opportunities and challenges around patient-centric trials and patient centricity in pharma.